DHA inhibits invasion and metastasis in NSCLC cells by interfering with CCL18/STAT3 signaling pathway
-
Published:2022-10-10
Issue:
Volume:
Page:
-
ISSN:1591-9528
-
Container-title:Clinical and Experimental Medicine
-
language:en
-
Short-container-title:Clin Exp Med
Author:
Luo Hai-qing,Huang Yu-meng,Li Jing,Tang Xu-dong,Chen Ran,Wang Yan,Ren Jing,Dai Qiu-qin,Lan Liu-bo,Chen Jiang-yan,Li Xiang-yong
Abstract
AbstractOmega-3 has been proposed as an antitumor substance that suppresses the growth and metastasis of multiple types of tumor cells, including lung cancer, but the specific mechanisms involved remain obscure. Our previous studies showed that the expression of chemokine ligand 18 was related to the migration and metastasis of non-small cell lung cancer. Here, we aim to explore whether omega-3 inhibits invasion and metastasis of NSCLC by regulating the expression of CCL18. The expression of CCL18, metastasis- and epithelial-mesenchymal transition (EMT)-related genes at mRNA and protein levels in NSCLC cell lines were detected by RT-qPCR and Western blot, respectively. The metastatic and invasive capability of NSCLC cells were evaluated by scratch wound healing and Transwell assays, respectively. Our results showed that the level of CCL18 is positively associated with metastatic ability of NSCLC cells. Docosahexaenoic acid, an important long-chain, polyunsaturated omega-3 (n−3) fatty acid, significantly inhibited invasion and metastasis of NSCLC cells, and concomitantly downregulated the expression of metastasis- and EMT-related genes and p-STAT3 signaling pathway. Additionally, we found that DHA inhibited CCL18 expression in lung cancer cells, while overexpression of CCL18 effectively reversed DHA-mediated downregulation in the expression of metastasis- and EMT-related genes and p-STAT3 signaling as well as DHA-mediated inhibitory effect on metastasis and invasion of NSCLC cells. DHA inhibits NSCLC cell invasion and metastasis possibly through targeted inhibition of CCL18/ STAT3 signaling pathway and EMT process.
Funder
Guangdong Province Natural Science Foundation
Zhanjiang Science and Technology Development Special Fund Competitive Allocation Project
Affiliated Hospital of Guangdong Medical University Clinical Research Project In Hospital Fund
Affiliated Hospital of Guangdong Medical University Clinical medicine+
Guangdong Medical University Scientific Research Foundation of Natural Science Key Cultivation Project
Guangdong Medical University College Students' Innovation Experiment Project
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference29 articles.
1. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40.
2. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thora Oncol. 2022;17(3):362–87.
3. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001.
4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.
5. Zhao H, Wang J, Kong X, et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci Rep. 2016;6:29719.